Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzutifan vs everolimus in advanced renal cell carcinoma after PD-1/L1 and VEGF-targeted therapies
2019-003444-72Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of belzutifan in clear cell renal cell carcinoma (ccRCC) (2 arms), sponsored by Merck & Co. Primary endpoint: Progression-free survival by BICR (RECIST 1.1). Started Jan 2020; status: active.
02
Drugs
belzutifan
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2019-003444-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003444-72.